Late-breaking clinical trials
Links shared publicly online about this topic.
- 286total visits
Late-breaking clinical trials
View full resource at eurekalert.org
Tags: Asthma, COPD, Tuberculosis, Clinical Trial, Women's Health, Pregnancy, Emphysema
Most Recently Shared on May 17, 2011 at 9:00 pm By:
Late-breaking clinical trials: Results from C91 "Late-Breaking Clinical Trials" on Tuesday afternoon, May 17, wi... http://bit.ly/lVmJyn
Clinical Trials 101 » RX 4 Sanity
rx4sanity.com — “Clinical Trials 101 » RX 4 Sanity” View full resource at rx4sanity.com
Most Recently Shared on May 11, 2012 at 7:28 pm By:
Patricia Raymond Doctor, Internist, Gastroenterologist, and Physician
Is being a "guinea pig" worth it? Will they make you sleep on pencil shavings and run inside a giant tube? http://t.co/Km0SQ9cy
Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD
news-medical.net — “Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules. In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.” View full resource at news-medical.net
Most Recently Shared on May 11, 2012 at 3:17 pm By:
Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD: Cytochroma today announced positive cl... http://t.co/nxC99L0j
Two types of stent systems are both effective in treating iliac artery disease
news-medical.net — “Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease (PAD), according to results of the MOBILITY trial presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.” View full resource at news-medical.net
Most Recently Shared on May 11, 2012 at 11:07 am By:
Two types of stent systems are both effective in treating iliac artery disease: Two types of stent systems are b... http://t.co/DMmUcMCi
New data on cystic fibrosis drug lifts Vertex stock - Business - The Boston Globe
bostonglobe.com — “Shares of Vertex Pharmaceuticals Inc. surged more than 55 percent Monday after the company released interim data showing an experimental drug combination dramatically improved breathing for some cystic fibrosis patients taking it in a clinical trial. The Cambridge company’s stock closed at $58.12, up $20.71 - or 55.3 percent - on the Nasdaq exchange. Vertex gained $4.2 billion in market value, in the largest one-day stock increase since the biotechnology firm went public 22 years ago.” View full resource at bostonglobe.com
Most Recently Shared on May 8, 2012 at 5:15 am By:
Drugs and Devices OW OW Health
New data on cystic fibrosis drug lifts Vertex stock - Boston Globe: Boston GlobeNew data on cystic fibrosi... http://t.co/oeshXbtI #drug
Napo Comments on FDA Announcing Extension of Crofelemer NDA Priority Review
drugs.com — “Crofelemer is a new drug in development for the treatment of secretory diarrhea, including HIV-associated diarrhea, pediatric diarrhea, acute infectious diarrhea and diarrhea-predominant irritable bowel syndrome. Crofelemer information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on May 8, 2012 at 3:01 am By:
Drugs and Devices OW OW Health
Napo Comments on FDA Announcing Extension of Crofelemer NDA Priority Review: SAN FRANCISCO--(BUSINESS WIRE... http://t.co/zqa9J7eg #drug
Talon Therapeutics Receives Notification of Three Month PDUFA Date Extension for Marqibo
drugs.com — “Marqibo (vincristine sulfate liposomes injection) is a new drug formulation in development for the treatment of the treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) and non-Hodgkin's Lymphoma. Marqibo information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on May 8, 2012 at 3:01 am By:
Drugs and Devices OW OW Health
Talon Therapeutics Receives Notification of Three Month PDUFA Date Extension for Marqibo: SAN MATEO, Calif... http://t.co/fJfnZSyp #drug
Allergy, Asthma and Immunology - Childrens Hospital of Michigan
childrensdmc.org — “Children's HIV Pediatric AIDS Clinical Trials Group. Children's Hospital of Michigan Pediatric Immunology, Rheumatology, Allergy and Asthma Services For Newborns, Infants, Children and Adults. Individualized Treatment Plans Provide Best Chance of Normal Outcome.” View full resource at childrensdmc.org
Most Recently Shared on May 7, 2012 at 6:01 pm By:
Children's DMC Hospital and Children's Hospital
Our Allergy, Asthma & Immunology Division has a history of excellence in care for asthma, allergies & immune deficiency http://t.co/WG7MEiqz
Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia - MPR
empr.com — “Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.” View full resource at empr.com
Most Recently Shared on May 7, 2012 at 5:18 pm By:
Phase 3 Study of #Aripiprazole Intramuscular Depot for the Maintenance Treatment of #Schizophrenia http://t.co/hAN0om32
Phase 3 Trial Update of Latuda for Bipolar I Depression - MPR
empr.com — “Dainippon Sumitomo Pharma announced results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of Latuda (lurasidone; Sunovion) as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).” View full resource at empr.com
Most Recently Shared on May 7, 2012 at 2:27 pm By:
Phase 3 Trial Update of #Latuda for #Bipolar I #Depression http://t.co/qSy2y0ba
Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression
news-medical.net — “Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).” View full resource at news-medical.net
Most Recently Shared on May 7, 2012 at 1:48 pm By:
Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression: Dainippon Sumitomo Pha... http://t.co/8V8xkekJ
Landes Bioscience Journals: Dermato-Endocrinology
landesbioscience.com — “Vitamin D deficiency is associated with a variety of skeletal, cardiometabolic, and immunologic co-morbidities that are present in chronic kidney disease (CKD). We performed a systematic review to investigate the effects of vitamin D supplementation, in the form of ergocalciferol or cholecalciferol, on various health outcomes in early CKD. Seventeen clinical trials were identified, only two of which were randomized, placebo controlled trials. The majority of studies supplementing with > 2000 IU/” View full resource at landesbioscience.com
Most Recently Shared on May 6, 2012 at 6:10 pm By:
Dr. Vin Tangpricha Doctor, Internist, Endocrinologist, and Physician
Vitamin D in early chronic kidney disease: A systematic review http://t.co/vwyL5kyU Published by Emory Colleagues @jalvar2 #VitaminD #Emory
Attending an FDA Hearing for Pfizer’s JAK: Tofacitinib CP-690550 | RA Education | Rheumatoid Arthritis Warrior
rawarrior.com — “Three years ago, one of the first friends I made through my blog was Angie. She got into a Pfizer clinical trial for tofacitinib (then called tasocitinib). She...” View full resource at rawarrior.com
Most Recently Shared on May 6, 2012 at 9:00 am By:
New Post: Attending an FDA Hearing for Pfizer’s JAK: Tofacitinib CP-690550 http://t.co/s71kIumW #rheum
Treating Patients Enrolled in Clinical Trials
onclive.com — “All oncology nurses—not just nurse researchers—will need to understand the fundamentals of clinical trials as patient access to the studies continues to expand.” View full resource at onclive.com
Most Recently Shared on May 5, 2012 at 5:29 pm By:
Treating Patients Enrolled in Clinical Trials http://t.co/td7Evcaa #ONScongress
Artificial Pancreas Android Phone at UVA RIGHT NOW!! - TuDiabetes - a community of people touched by diabetes
tudiabetes.org — “WOW, just got off the phone with clinical nurse manager at UVA's artificial pancreas division. they are doing trial in adolescents, a 10 hour study to see if t…” View full resource at tudiabetes.org
Most Recently Shared on May 5, 2012 at 5:37 am By:
Personal Medicine in Paducah, Kentucky. Dr Hodge was a featured speaker at the Mayo Clinic's Transform Symposium
in '09 and has been named by Brian Dolan of Mobi Heath News as "The
First iPhone Doctor". She is the author of The Personal Pediatrics Primer for the Progressive Parent.
Dr. Hodge's special interests in pediatrics include nutrition,
prevention and the potential for the internet to strengthen physician
patient relationships. Dr. Hodge is a member of the Health care
Information and Management Systems Society (HIMSS), a Fellow of the
Academy of Pediatrics' Quality and Innovation Network, and a founding
member of the Society for Participatory Medicine. Participatory Medicine
is an emerging group of engaged patients and physicians who believe
that mutual trust and understanding as well as use of media, health IT strengthens the physician patient relationship and provides for better care." /> Natalie Hodge, MD, FAAP Pediatrician, Physician, Active Health Library, and Doctor
Artificial Pancreas Android Phone at UVA RIGHT NOW!! - TuDiabetes - a community of people touched by diabetes http://t.co/nTxU3KMD
EHR alerts help recruit patients for clinical trials - FierceEMR
fierceemr.com — “Clinical trial alerts (CTAs) generated by electronic health records are subject to alert fatigue, but remain helpful in potential recruitment of participants in clinical trials, according to a new Read more...” View full resource at fierceemr.com
Most Recently Shared on May 4, 2012 at 3:32 pm By:
Perficient Health IT Health Business
Thanks @IThealthnonprof! RT @Perficient_HC: #EHR alerts help recruit patients for clinical trials http://t.co/1ab3OmQS #HITsm #HealthIT
Advertisement
